Cumulative incidence of AEs. Extended follow-up demonstrates continued incidence of all-grade atrial fibrillation (A), all-grade hypertension (B), and grade 3 or higher hypertension (C) for patients treated with ibrutinib compared with those treated with bendamustine plus rituximab.